Loncastuximab Tesirine-Lpyl: uses, dosing, side effects & brands
Loncastuximab Tesirine-Lpyl is a medicine sold in the U.S. under one brand, for diffuse large b-cell lymphoma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Diffuse Large B-Cell Lymphoma
- Available as
- Injectable
- Sold as
- Zynlonta
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How loncastuximab tesirine-lpyl is dosed
From the FDA label for Zynlonta (application BLA761196). Other loncastuximab tesirine-lpyl products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
ZYNLONTA is an intravenous infusion over 30 minutes on Day 1 of each cycle (every 3 weeks). The recommended dosage is: 0.15 mg/kg every 3 weeks for 2 cycles. 0.075 mg/kg every 3 weeks for subsequent cycles. ( 2.1 ) Premedicate with dexamethasone 4 mg orally or intravenously twice daily for 3 days beginning the day before ZYNLONTA. ( 2.2 ) See Full Prescribing Information for instructions on preparation and administration. ( 2.4 ) 2.1 Recommended Dosage ZYNLONTA as an intravenous infusion administered over 30 minutes on Day 1 of each cycle (every 3 weeks). Administer intravenous infusion as follows: 0.15 mg/kg every 3 weeks for 2 cycles. 0.075 mg/kg every 3 weeks for subsequent cycles. 2.2 Recommended Premedication Unless contraindicated, administer dexamethasone 4 mg orally or intravenously twice daily for 3 days beginning the day before administering ZYNLONTA. If dexamethasone administration does not begin the day before ZYNLONTA, dexamethasone should begin at least 2 hours prior to administration of ZYNLONTA. 2.3 Dosage Modifications and Delays Table 1: Recommended Dosage Modifications for Adverse Reactions Adverse Reactions Severity Dosage Modification Hematologic Adverse Reactions Neutropenia [see Warnings and Precautions (5.2) ] Absolute neutrophil count less than 1 × 10 9 /L Withhold ZYNLONTA until neutrophil counts returns to 1 × 10 9 /L or higher Thrombocytopenia [see…
Loncastuximab Tesirine-Lpyl side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Effusion and Edema [see Warnings and Precautions (5.1) ] Myelosuppression [see Warnings and Precautions (5.2)] Infections [see Warnings and Precautions (5.3) ] Hepatotoxicity, including DILI [see Warnings and Precautions(5.4) ] Cutaneous Reactions [see Warnings and Precautions (5.5) ] Most common (≥20%) adverse reactions, including laboratory abnormalities, are thrombocytopenia, increased gamma-glutamyltransferase, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema, nausea, and musculoskeletal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact ADC Therapeutics at 1-855-690-0340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to ZYNLONTA as a single agent at an initial dose of 0.15 mg/kg in 215 patients with DLBCL in studies ADCT-402-201 (LOTIS-2) and ADCT-402-101, which includes 145 patients from LOTIS-2 treated with 0.15 mg/kg × 2 cycles followed…
Who shouldn’t take loncastuximab tesirine-lpyl
None. None. ( 4 )
Every loncastuximab tesirine-lpyl product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Zynlonta.
What people report to the FDA about loncastuximab tesirine-lpyl
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 8 reports naming loncastuximab tesirine-lpyl, and the FDA flagged 88% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- cns ventriculitis4 reports
- hydrocephalus4 reports
- meningitis pneumococcal4 reports
- biliary obstruction1 reports
- fluid retention1 reports
- gamma-glutamyltransferase increased1 reports
- hepatic enzyme increased1 reports
- hypervolaemia1 reports
Read these as a signal, not a rate. A report does not mean loncastuximab tesirine-lpyl caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is loncastuximab tesirine-lpyl?
Zynlonta (Loncastuximab Tesirine-Lpyl) is a medication used to treat Diffuse Large B-Cell Lymphoma.
Can you take loncastuximab tesirine-lpyl with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run loncastuximab tesirine-lpyl against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does loncastuximab tesirine-lpyl come in?
Across the brands we track, loncastuximab tesirine-lpyl is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic loncastuximab tesirine-lpyl?
We do not currently list a generic-labelled loncastuximab tesirine-lpyl product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Loncastuximab Tesirine-Lpyl: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/loncastuximab-tesirine-lpyl
- MLA
- “Loncastuximab Tesirine-Lpyl: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/loncastuximab-tesirine-lpyl.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for loncastuximab tesirine-lpyl on DailyMed (NIH) ↗.